Roscovitine (Seliciclib,CYC202)

Catalog No.S1153

Roscovitine (Seliciclib,CYC202) Chemical Structure

Molecular Weight(MW): 354.45

Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 147 In stock
USD 470 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 16 Publications

5 Customer Reviews

  • In vitro inhibition of mouse corticotroph tumor cells by R-roscovitine. (A) Treatment of ACTH-secreting AtT20 cells with R-roscovitine (1-2 × 10-5 μM) led to decreased number of viable cells at 24 and 48 h, as depicted by Wst-1 proliferation assay (mean ± SE; **P < 0.01). (B) Western blot of protein extracts derived from AtT20 cells treated with vehicle or R-roscovitine. (C) R-roscovitine treatment (10 μM) for 48 h induced senescence as indicated by increased β-gal expression. (D) ACTH concentration by radioimmunoassays of culture medium from AtT20 cells treated with vehicle or R-roscovitine (mean ±SE; **P < 0.01 and ***P < 0.001). (E) Western blot of protein extracts derived from AtT20 cells treated with R-roscovitine. Vehicle is 0.2% DMSO.

    PNAS 2011 108, 8417. Roscovitine (Seliciclib,CYC202) purchased from Selleck.

    In vivo action of R-roscovitine inmouse corticotroph adenomas. Athymic nude mice were s.c. inoculated with corticotroph tumor AtT20 cells (1 × 105 cells). Three days after injection, mice were randomized to receive Rroscovitine (150 mg/kg) or vehicle by oral gavage twice daily, 5 d/wk. After 3 wk, tumor xenografts were dissected and (A) tumor volumes were decreased in R-roscovitine-treated animals. (B) Western blot of representative tumor specimens showed decreased ACTH and PCNA expression in R-roscovitine-treated tumors. (C) R-roscovitine-treated corticotroph tumors exhibited decreased PCNA and ACTH coexpressing cells. Fluorescence microscopy image of immunohistochemistry detecting PCNA (red) and ACTH (green) expression in control (a-c) and R-roscovitine-treated tumors (d-f). Cryosection slides were counterstained with DAPI (blue). (D) Blood was collected from each animal for measurement of plasma ACTH and serum corticosterone levels (mean ±SE; n = 13-14 mice for each group; **P < 0.01).

    PNAS 2011 108, 8417. Roscovitine (Seliciclib,CYC202) purchased from Selleck.

  • Inhibition of CDK5 by roscovitine resulted in defective neuronal migration, which was rescued by expression of GFP-Ndel1 (S251E). a, Granular neurons were treated with roscovitine. Western blotting was performed 24 h after start of culture. Aurora-A and NDEL1 displayed similar expression levels with untreated neurons, whereas the levels of phosphorylated Aurora-A and NDEL1 proteins were decreased after treatment with roscovitine. Relative intensities of the bands of Western blotting are shown at the bottom.

    J Hematol Oncol 2012 7, 53. Roscovitine (Seliciclib,CYC202) purchased from Selleck.

    (a-c) Relative viability of Cis-R cells and parental MDA-MB-231 (Cis-S) cells in the presence of cisplatin (10 μM) and the increasing concentrations of WEE1i (a), ATRi (b) and CHK1i (c). (d) Illustration of the experimental setup, with incorporation of IdU and CldU shown in red and green, respectively. (e) As shown in (d), MDA-MB-231 cells were incubated with IdU for 10 min as indicated, followed by cisplatin treatment for 3 hours, with or without indicated inhibitor(s) (top) for indicated total 40 min and CIdU was applied for 10 min. Cells were fixed and stained with IdU and CIdU antibodies. Nuclear DNA was counterstained by DAPI. (f) Quantification of indicated part of three separate experiments as in (e) represented as the mean ± SEM. CDKi:Roscovitine.

    Sci Rep, 2017, 7:43517. Roscovitine (Seliciclib,CYC202) purchased from Selleck.

  •  

    Chronic treatment with roscovitine attenuates the development of atherosclerosis in ApoE-/- mice. Vehicle, roscovitine or resveratrol were daily administered to ApoE-/- mice under high fat high cholesterol diet, from the age of four weeks old. After 18 weeks of treatment, Oil-Red-O (A) and SA-β-gal (B) staining was performed using aortae collected from all groups of mice.Chronic treatment with roscovitine attenuates the development of atherosclerosis in ApoE-/- mice. Vehicle, roscovitine or resveratrol were daily administered to ApoE-/- mice under high fat high cholesterol diet, from the age of four weeks old. After 18 weeks of treatment, Oil-Red-O (A) and SA-β-gal (B) staining was performed using aortae collected from all groups of mice.

    University of Hong Kong. Roscovitine (Seliciclib,CYC202) purchased from Selleck.

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.
Targets
CDK5/p35 [1]
(Cell-free assay)
Cdc2/CyclinB [1]
(Cell-free assay)
CDK2/CyclinA [1]
(Cell-free assay)
CDK2/CyclinE [1]
(Cell-free assay)
ERK2 [1]
(Cell-free assay)
0.16 μM 0.65 μM 0.7 μM 0.7 μM 14 μM
In vitro

Roscovitine displays high efficiency and high selectivity towards some cyclin-dependent kinases with IC50 of 0.65, 0.7, 0.7 and 0.16 μM for cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E and cdk5/p53, respectively. [1] Roscovitine reversibly inhibits the prophaselmetaphase transition in the micromolar range of starfish oocytes and sea urchin embryos, inhibits in vitro M-phase-promoting factor activity and in vitro DNA synthesis in Xenopus egg extracts, and suppresses the proliferation of mammalian cell lines with an average IC50 of 16 μM. [1] In mesangial cells, Roscovitine results in a dose-dependent reduction of CDK2 activity that at concentrations of 7.5, 12.5 and 25 mM, Roscovitine causes a 25, 50% and 100% decrease in CDK2 activity, respectively. [2] A recent study shows that Roscovitine inhibits cdk5 kinase activity, cell proliferation, multicellular development, and cdk5 nuclear translocation in Dictyostelium discoideum, without affecting the expression of cdk5 protein during axenic growth. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A3-KAW M37qNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TjPWlEPTB;NT63OlEyPiEQvF2= NV63e3huW0GQR1XS
MRK-nu-1 M1PXdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\pTWM2OD15LkGyPVY6KM7:TR?= NY\1SY11W0GQR1XS
NCCIT M1rSSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoexTWM2OD15LkW1OFgzKM7:TR?= NFHCPFhUSU6JRWK=
JiyoyeP-2003 MkfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17h[WlEPTB;OD61NFI3PCEQvF2= NUKzd2pbW0GQR1XS
KS-1 M4PPbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTlwNEW3PFUh|ryP NG\ublZUSU6JRWK=
Becker MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vpc2lEPTB;OT60OlA5OiEQvF2= NW\TXJFIW0GQR1XS
KARPAS-422 NG\1cIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{mzcmlEPTB;OT65OlM{PiEQvF2= MnnoV2FPT0WU
BB65-RCC NXnMWFZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDEc29YUUN3ME25Mlk4PDl3IN88US=> NH3iOIFUSU6JRWK=
SK-UT-1 MmnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTFyLkO1JO69VQ>? NYr4XWFiW0GQR1XS
ST486 NVG4RXF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTFyLkO1NUDPxE1? NUCxbZp3W0GQR1XS
LB831-BLC Mn;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIK2fo9KSzVyPUGxMlU3OjRizszN MV;TRW5ITVJ?
COR-L279 M1f2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUn1WGpZUUN3ME2xNk4zQTB5IN88US=> NEHLelJUSU6JRWK=
NB1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofsTWM2OD1zMj6zN|A5KM7:TR?= MYfTRW5ITVJ?
D-247MG M1W1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTF{LkO1NVYh|ryP MnXPV2FPT0WU
697 NUPU[pZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTF{Lk[wNFch|ryP M1z6fHNCVkeHUh?=
GCIY NVHicpVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTF{Lki2NVMh|ryP NHLacGxUSU6JRWK=
RPMI-8402 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrYTWM2OD1zMz62NlYzKM7:TR?= MV;TRW5ITVJ?
Raji NXvmO2ZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGS5UVZKSzVyPUGzMlc5QTRizszN MonpV2FPT0WU
MEG-01 NHfmbZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjYZlhqUUN3ME2xN{45Ozd7IN88US=> NFSwWIVUSU6JRWK=
RPMI-6666 NEThRWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPjTZNKSzVyPUGzMlkyOjFizszN NFzVWlhUSU6JRWK=
SCC-3 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DLZmlEPTB;MUSuNlk2PiEQvF2= NUDIfWZGW0GQR1XS
HCC1599 Ml7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYOzZnBxUUN3ME2xOE42QTd3IN88US=> MUXTRW5ITVJ?
OCI-AML2 NGXBOnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTF3Lk[0PFIh|ryP NHLSXXJUSU6JRWK=
OS-RC-2 M2nDNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnre21DUUN3ME2xOU45Ozh{IN88US=> MUjTRW5ITVJ?
NCI-H1304 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXG1bGhqUUN3ME2xOk4{PjBzIN88US=> M2C5dXNCVkeHUh?=
HD-MY-Z M2jXNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\TTWM2OD1zNj64NlQ3KM7:TR?= MYXTRW5ITVJ?
JAR M{W1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTF5LkCxOVIh|ryP MVfTRW5ITVJ?
TGW MoC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTF5LkixNlQh|ryP NH\CeVhUSU6JRWK=
BC-3 Ml;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfIcpZKSzVyPUG4MlA{ODVizszN MmjaV2FPT0WU
A101D MmHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\4TWM2OD1zOD6zNlA5KM7:TR?= Mmr2V2FPT0WU
COLO-320-HSR M1ywTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknoTWM2OD1zOD63Olg5KM7:TR?= M{LsNHNCVkeHUh?=
LC4-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\lZmlEPTB;MUiuPFc{PCEQvF2= M3T0enNCVkeHUh?=
BC-1 NIe1cGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTITJlJUUN3ME2xPU4yOTl6IN88US=> NIrOfYtUSU6JRWK=
MHH-PREB-1 NUHOcmVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zMSWlEPTB;MkCuNFM2PiEQvF2= MXnTRW5ITVJ?
BL-70 NUnvVZRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3SenM6UUN3ME2yNE4{Ojd2IN88US=> MnnKV2FPT0WU
CESS NWHXWoZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX32XZJDUUN3ME2yNE45PTR7IN88US=> NFLFXINUSU6JRWK=
ES8 M1PyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPXSG45UUN3ME2yNU4xPiEQvF2= M4rqcXNCVkeHUh?=
NOMO-1 NIfUWWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonqTWM2OD1{MT6yNFA5KM7:TR?= M3\wVXNCVkeHUh?=
ACN MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGCxXWVKSzVyPUKxMlM{QDlizszN NYTtVJpHW0GQR1XS
EB-3 NX3U[2lwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTJ|LkG4N|Eh|ryP MVTTRW5ITVJ?
LS-513 M3zifmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTJ|LkWxO|kh|ryP NIDQfHFUSU6JRWK=
HH MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV70RYJ2UUN3ME2yOE4{QDF7IN88US=> NYmzSFBMW0GQR1XS
IST-SL2 NGrZSIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoiyTWM2OD1{ND61N|Q{KM7:TR?= MXTTRW5ITVJ?
HOP-62 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjHTWM2OD1{NT60OFI2KM7:TR?= NVLSNo1[W0GQR1XS
NCI-H2126 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHv[5RUUUN3ME2yOU43PTJ7IN88US=> MV3TRW5ITVJ?
BL-41 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17LcWlEPTB;MkWuPVU6PyEQvF2= MVnTRW5ITVJ?
KURAMOCHI NH3hXmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTJ4LkiwPFIh|ryP NWXSTnZDW0GQR1XS
KARPAS-299 NUHOdoRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYC5bXFTUUN3ME2yOk45PjR4IN88US=> M{CxcnNCVkeHUh?=
QIMR-WIL MonqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;2U3I5UUN3ME2yO{46OTR2IN88US=> NXzKWIg3W0GQR1XS
HL-60 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDpPGpKSzVyPUK3Mlk5PjlizszN M4HRNHNCVkeHUh?=
TE-9 MlLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPPTWM2OD1{OD63PVY6KM7:TR?= NVyzdW1NW0GQR1XS
TE-8 NFziSmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHiZ5R1UUN3ME2yPE46ODhizszN M{ewTHNCVkeHUh?=
NOS-1 MkK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfBZnVKSzVyPUK4Mlk4OzNizszN MWLTRW5ITVJ?
GI-1 NXvTUlBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTJ7LkCxNVMh|ryP NXXGNWR{W0GQR1XS
KM12 MkLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPnPFhKSzVyPUK5MlYzOzlizszN M4LtNnNCVkeHUh?=
BB30-HNC NEPxSoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHmzeHNKSzVyPUK5Mlk1QDNizszN M1TacHNCVkeHUh?=
ES3 NFToT41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIWy[mZKSzVyPUK5Mlk2QDJizszN NFqxe45USU6JRWK=
NCI-H510A MmLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTNyLkCzNlkh|ryP MoXHV2FPT0WU
NCI-H82 M3\0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH[1UopKSzVyPUOxMlAyOzVizszN NUHqUZhyW0GQR1XS
NCI-SNU-1 M4X5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrGcmZMUUN3ME2zNU4yODV7IN88US=> Mom4V2FPT0WU
NKM-1 M{\0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTNzLkGzPVch|ryP M{DWSnNCVkeHUh?=
SIG-M5 NUPlc4lXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HzfWlEPTB;M{GuOlg{OyEQvF2= NFHCZYhUSU6JRWK=
SK-N-FI MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfFTWM2OD1|MT63OVM2KM7:TR?= MUTTRW5ITVJ?
LOUCY NFnxOJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHmTWM2OD1|Mj6xNlU{KM7:TR?= M3y5N3NCVkeHUh?=
Calu-6 NG\S[4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLpNnU{UUN3ME2zNk41PzR3IN88US=> NXvaNpNFW0GQR1XS
GOTO M{TXW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTN{LkmxNlkh|ryP M{mwS3NCVkeHUh?=
NCI-H526 M3;DRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnYUFlKSzVyPUOzMlQ6OzZizszN MnzxV2FPT0WU
RKO M1SxUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTN|LkW5Olkh|ryP NUfiN4pzW0GQR1XS
NCI-H64 M1rrVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnywTWM2OD1|Mz64OVk4KM7:TR?= NUG0Wmt5W0GQR1XS
LP-1 MnG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDlTWM2OD1|Mz64PVA5KM7:TR?= M1f5XnNCVkeHUh?=
KGN NYjmfoFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TYcmlEPTB;M{SuNlUzPCEQvF2= NWnjPJh{W0GQR1XS
NCI-H2141 M3:0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTN2Lk[1N|Mh|ryP M3vJXnNCVkeHUh?=
TE-10 M{Gyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HIe2lEPTB;M{SuPVQzOiEQvF2= M1z6T3NCVkeHUh?=
K5 NYDqTVRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnOTWM2OD1|NT6wPFYyKM7:TR?= M2f4cnNCVkeHUh?=
IMR-5 NEXUbI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M16yTGlEPTB;M{WuN|E{QSEQvF2= NICwcpRUSU6JRWK=
TE-441-T M{PFTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TnbWlEPTB;M{[uNVE1QCEQvF2= M2juXnNCVkeHUh?=
TE-6 NYDVe|RWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXLTWM2OD1|Nj6zNlQ3KM7:TR?= NUKyemVVW0GQR1XS
MOLT-4 M2jP[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XWTmlEPTB;M{[uN|I4PiEQvF2= MknUV2FPT0WU
COLO-684 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLxOVVKSzVyPUO3MlAyOiEQvF2= NEnTfVVUSU6JRWK=
LU-139 NFrzVIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPuUGpKSzVyPUO3MlE5PTZizszN MY\TRW5ITVJ?
OPM-2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILLbW1KSzVyPUO3MlI6PDlizszN MkfYV2FPT0WU
ML-2 M2KxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTzTWM2OD1|Nz62O|EzKM7:TR?= M13p[XNCVkeHUh?=
RS4-11 M1;5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HvSWlEPTB;M{euO|A3QSEQvF2= M1PYVnNCVkeHUh?=
MONO-MAC-6 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\ITFZKSzVyPUO4MlI1PzdizszN MULTRW5ITVJ?
NCI-H345 M3XkfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnETpJKSzVyPUO4MlkyODZizszN MmXGV2FPT0WU
NTERA-S-cl-D1 MmT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmq4TWM2OD1|OT61PFQzKM7:TR?= MnHZV2FPT0WU
NCI-H1882 M2DXNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTiPY9EUUN3ME20NE42QTl6IN88US=> M{Lye3NCVkeHUh?=
LC-1F M{SxZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoG2TWM2OD12MT61O|A2KM7:TR?= NHLEdGhUSU6JRWK=
HT NETOR3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWK2U2FWUUN3ME20Nk4xODJ6IN88US=> M1HHeHNCVkeHUh?=
MLMA Mn\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTR{LkK3PFch|ryP M4nkNHNCVkeHUh?=
DG-75 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DKWGlEPTB;NEKuOlU1PiEQvF2= MlrUV2FPT0WU
GI-ME-N NILsWoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTR{Lk[2O|Eh|ryP NXq0cIZRW0GQR1XS
MS-1 NUL1eo5wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PPVmlEPTB;NEKuPFk{KM7:TR?= MWXTRW5ITVJ?
CGTH-W-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TYcmlEPTB;NESuPVY6PyEQvF2= M3TpWnNCVkeHUh?=
NCI-H209 MlH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFviZlVKSzVyPUS2MlAyOTVizszN MkTmV2FPT0WU
LB2518-MEL MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHEdmpKSzVyPUS3MlA1PDhizszN MXjTRW5ITVJ?
DU-4475 NWP3[oxtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3L4WWlEPTB;NEiuOFk{PyEQvF2= MXjTRW5ITVJ?
LB2241-RCC NUi0[ZNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTR6Lk[yNFIh|ryP NHPrdW5USU6JRWK=
LB771-HNC MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTR6LkmyNVIh|ryP M3LUdXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Roscovitine, at a dose of 50 mg/kg, significantly inhibits growth of The Ewing's sarcoma family of tumors (ESFT) xenografts. [4] Roscovitine enhances the antitumor effect of doxorubicin without increased toxicity with a mechanism that involves cell cycle arrest rather than apoptosis in nude mice bearing established MCF7 xenografts. [5]

Protocol

Kinase Assay:[1]
+ Expand

Enzymes :

Kinases activities are assayed at 30 °C in buffer C. Blank values are subtracted from the data and activities calculated as molar amount of phosphate incorporated in protein acceptor during a 10-minute incubation. Controls are performed with appropriate dilutions of DMSO. In a few cases, phosphorylation of the substrate is assessed by autoradiography after SDS/PAGE. p34cdc2/cyclin B is purified from M-phase starfish (M. glacialis) oocytes by affinity chromatography. It is assayed with 1 mg histone Hl/mL, in the presence of 15 μM [γ-32P]ATP (3000 Ci/mmol; 1 mCi/mL) in a final volume of 30 μL. After a 10-minute incubation at 30 °C, 25-μL aliquots of supernatant are spotted onto pieces of Whatman P81 phosphocellulose paper, and, after 20 seconds, the filters are washed five times (for at least 5 minutes each time) in a solution of 10mL phosphoric acid/L water. The wet filters are transferred into 6-mL plastic scintillation vials, 5 mL ACS scintillation fluid is added and the radioactivity measured in a Packard counter. The kinase activity is expressed as molar amount of phosphate incorporated in histone H1 during a 10-minutes incubation or as a percentage of maximal activity. p33cdk2/cyclin A and p33cdk2/cyclinE are reconstituted from extracts of sf9 insect cells infected with various baculoviruses. Cyclins A and E are fusion proteins with glutathione S-transferase and the complexes are purified on glutathione-agarose beads. Kinase activities are assayed with 1 mg/mL histone H1, in the presence of 15 μM [γ-32P]ATP, during 10 minutes, in a final volume of 30 μL, as described for the p34cdc2/cyclin B kinase. p33cdk5/p35 is purified from bovine brain, excluding the Mono S-chromatographic step. The active fractions from the Superose 12 column are pooled and concentrated to a final concentration of approximately 25 μg enzyme/mL. The kinase is assayed with 1 mg/mL histone HI in the presence of 15 μM [γ-32P]ATP, during 10 minutes in a final volume of 30 μL, as described for the p34cdc2/cyclin B kinase. p33cdk5/cyclin D1 is obtained from insect cell lysates. Cdk4 is a fusion protein with glutathione-S-transferase and the active complex is purified on glutathione-agarose beads. Its kinase activity is assayed with purified retinoblastoma protein (complexed with glutathione-S-transferase) in the presence of 15 μM [γ-32P]ATP, in a final volume of 30 μL. After a 15-minute incubation, 30 μL Laemmli sample buffer is added. The phosphorylated substrate is resolved by 10 % SDS/PAGE and analysed by autoradiography by overnight exposure to Hyperfilm MP and densitometry. p33cdk4/cyclinD 2 is obtained from insect cell lysates. It is assayed with purified retinoblastoma protein (complexed with glutathione-S-transferase) in the presence of 15 μM [γ-32P]ATP in a final volume of 30 μL. After a 30-minute incubation, 30 μL Laemmli sample buffer is added. The phosphorylated substrate is resolved by 10% SDS/PAGE and analysed by autoradiography by overnight exposure to Hyperfilm MP and densitometry. MAP kinase erkl (tagged with glutathione-S-transferase), is expressed in bacteria, purified on glutathione-agarose beads and assayed with 1 mg myelin basic protein/ml in the presence of 15 μM [γ-32P]ATP as described above for the p34cdc2cyclin B kinase. His-tagged erkl and erk2 are activated in vitro by mitogen-activated protein kinase kinase, purified (Ni-affinity and Mono Q) and assayed as described above during 10 minutes in a final volume of 30 μL. Protein kinase C isoforms are purified from baculovirus infected sf9 insect cells and assayed with 1 mg/mL protamine sulfate in the presence of 15 μM [γ-32P]ATP, during 10 minutes at 30 °C, in a final volume of 30 μL. Phosphorylated protamine sulfate is recovered on Whatman P81 phosphocellulose paper as described for the cdc2 kinase. The catalytic subunit of cAMP-dependent protein kinase, purified from bovine heart, is assayed with 1 mg histone Hl/ml, in the presence of 15 μM [γ-32P]ATP as described for the p34cdc2/cyclin B kinase. cGMP-dependent protein kinase, purified to homogeneity from bovine tracheal smooth muscle, is assayed with 1 mg histone Hl/mL, in the presence of 15 μM [γ-32P]ATP as described for the p34cdc2/cyclin B kinase. Casein kinase 2 is isolated from rat liver cytosol and assayed with 1 mg casein/mL and 15 μM [γ-32P]ATP. The substrate is spotted on Whatmann 3MM filters and washed with 10% (mass/vol.) trichloroacetic acid. Myosin light chain kinase, purified from chicken gizzard is assayed in the presence of 100 nM calmodulin, 100 μM CaCl2, 50 mM Hepes, 5 mM MgCI,, 1 mM dithiothreitol and 0.1 mg BSA/ml at pH 7.5 using a synthetic peptide based on the smooth-muscle myosin light-chain phosphorylation site and in the presence of 15 μM [γ-32P]ATP, in a final volume of 50 μL. Incorporation of radioactive phosphate is monitored on phosphocellulose filters as described above. ASK-γ, a plant homologue of GSK-3, is expressed as a glutathione-S-transferase fusion protein in Escherichia coli and purified on glutathione-agarose. ASK-γ kinase is assayed, for 10 minutes at 30 °C, with 5 μg myelin basic protein, in the presence of 15 μM [γ-32P]ATP in a final volume of 30 μL. The phosphorylated myelin basic protein is recovered on Whatman P81 phosphocellulose paper as described for the p34cdc2/cyclin B kinase. Insulin receptor tyrosine kinase domain (CIRK-41) is overexpressed in a baculovirus system and purified to homogeneity. Its kinase activity is assayed, for 10 minutes at 30 °C, with 5 μg Raytide, in the presence of 15 μM [γ-32P]ATP, in a final volume of 30 μL. The phosphorylated Raytide is recovered on Whatman P81 phosphocellulose paper as described for the p34cdc2/cyclin B kinase. c-src kinase is purified from infected Sf9 cells. The v-abl kinase is expressed in E. coli and affinity purified on IgG Affigel 10. Both kinases are assayed for 10 minutes at 30 °C, with 5 μg Raytide, in the presence of 15 μM [γ-32P]ATP, in a final volume of 30 μL. The phosphorylated Raytide is recovered on Whatman P81 phosphocellulose paper as described for the p34cdc2/cyclin B kinase.
Cell Research:[1]
+ Expand
  • Cell lines: Leukemia, non-small cell lung cancer, colon cancer, central nervous system cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, breast cancer
  • Concentrations: 0.01 - 100 μM
  • Incubation Time: 48 hours
  • Method: 60 human tumour cell lines comprising nine tumor types are cultured for 24 hours prior to a 48-hour continuous exposure to 0.01-100 μM roscovitine. A sulforhodaminine B protein assay is used to estimate the cytotoxicity.
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: A4573 cells are injected s.c. into the right posterior flank of CD1 nu/nu mice.
  • Formulation: Roscovitine is dissolved in either absolute methanol or DMSO and then diluted in 10% Tween 80, 20% N-N-dimethylacetamide, and 70% polyethylene glycol 400.
  • Dosages: ≤50 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 71 mg/mL (200.31 mM)
Ethanol 6 mg/mL (16.92 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% DMSO+10% Tween 80+20% N-N-dimethylacetamide+69% PEG 400
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 354.45
Formula

C19H26N6O

CAS No. 186692-46-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03774446 Recruiting Cushing Disease Cedars-Sinai Medical Center November 2 2018 Phase 2
NCT03774446 Recruiting Cushing Disease Cedars-Sinai Medical Center November 2 2018 Phase 2
NCT02649751 Terminated Cystic Fibrosis University Hospital Brest|ManRos Therapeutics|Cyclacel Pharmaceuticals Inc. February 22 2016 Phase 2
NCT02649751 Terminated Cystic Fibrosis University Hospital Brest|ManRos Therapeutics|Cyclacel Pharmaceuticals Inc. February 22 2016 Phase 2
NCT02160730 Terminated Cushings Disease Shlomo Melmed MD|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Cedars-Sinai Medical Center May 2014 Phase 2
NCT02160730 Terminated Cushings Disease Shlomo Melmed MD|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Cedars-Sinai Medical Center May 2014 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How can I reconstitute the drug for in vivo studies?

  • Answer:

    S1153 in 1% DMSO+10% Tween 80+20% N-N-dimethylacetamide+PEG 400 is a clear solution which is okay for injection. And S1153 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension, which is fine for oral gavage.

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

Related CDK Products5

Tags: buy Roscovitine (Seliciclib,CYC202) | Roscovitine (Seliciclib,CYC202) supplier | purchase Roscovitine (Seliciclib,CYC202) | Roscovitine (Seliciclib,CYC202) cost | Roscovitine (Seliciclib,CYC202) manufacturer | order Roscovitine (Seliciclib,CYC202) | Roscovitine (Seliciclib,CYC202) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID